Morning Analysis on Biotech Equities -- Hemispherx Biopharma, Celldex Therapeutics, Intrexon, Incyte, and Idera Pharma
LONDON, March 24, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Celldex Therapeutics Inc. (NASDAQ: CLDX), Intrexon Corporation (NYSE: XON), Incyte Corporation (NASDAQ: INCY), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free research report on Hemispherx Biopharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Hemispherx%20Biopharma&d=24-Mar-2015&s=HEB. The US markets on Monday, March 23, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 18,116.04, down 0.06% and the NASDAQ Composite closed at 5,010.97, down 0.31%. The S&P 500 finished the session 0.17% lower at 2,104.42. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 864.02, down 0.28%, whereas the index has advancing 9.41% in the previous three months. Register for your complimentary reports at the links given below.
Shares in Hemispherx Biopharma Inc. gained 2.22%, to close the day at $0.23. The stock recorded a trading volume of 1.41 million shares, below its three months average volume of 1.87 million shares. The company's shares oscillated between $0.23 and $0.24 during the session. Over the last one month and over the previous three months, Hemispherx Biopharma Inc.'s shares have fallen by 3.00% and 2.95%, respectively. Further, the stock has declined 50.71% in the past one year. The company is trading below its 50-day and 200-day moving averages. Hemispherx Biopharma Inc.'s 200-day moving average of $0.28 is above its 50-day moving average of $0.24. Additionally, the stock has a Relative Strength Index (RSI) of 43.35. Sign up and read the free notes on HEB at:
http://get.Investor-Edge.com/pdf/?c=Hemispherx%20Biopharma&d=24-Mar-2015&s=HEB
On Monday, shares in Celldex Therapeutics Inc. recorded a trading volume of 2.70 million shares, higher than its three months average volume of 2.27 million shares. The stock ended the day at $28.53, which was 6.09% below its previous day's closing of $30.38, and registered an intraday range of $28.29 and $30.50. Celldex Therapeutics Inc.'s shares have surged 15.37% in the last one month, 65.30% in the previous three months, and 32.57% in the past one year. The company is trading above its 50-day and 200-day moving averages of $23.76 and $17.78, respectively. Furthermore, shares of Celldex Therapeutics Inc. have an RSI of 65.57. The complimentary notes on CLDX can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Celldex%20Therapeutics&d=24-Mar-2015&s=CLDX
Intrexon Corp.'s stock plummeted 5.27% to end Monday's session at $43.68. The stock recorded a trading volume of 1.25 million shares, below its three months average volume of 1.39 million shares. The company's shares fluctuated between $43.22 and $45.43 during the session. Intrexon Corp.'s shares have rallied 55.22% in the past one year. Further, the stock has gained 6.12% in the last one month and 71.16% in the previous three months. The company is trading above its 50-day and 200-day moving averages. Intrexon Corp.'s 50-day moving average of $37.71 is above its 200-day moving average of $26.38. Additionally, the stock has an RSI of 58.40. Register for free on Investor-Edge and access the latest research on XON at:
http://get.Investor-Edge.com/pdf/?c=Intrexon&d=24-Mar-2015&s=XON
On Monday, Incyte Corp.'s stock fluctuated between $92.35 and $94.96 before ending the session 2.26% lower at $93.40. The stock reported a trading volume of 1.03 million shares, lower than its three months average volume of 1.16 million shares. Incyte Corp.'s stock has surged 11.97% in the last one month, 34.23% in the previous three months, and 57.20% in the past one year. The company is trading above its 50-day and 200-day moving averages of $82.05 and $63.87, respectively. Moreover, shares of Incyte Corp. have an RSI of 70.24. The complete research on INCY is available for free at:
http://get.Investor-Edge.com/pdf/?c=Incyte&d=24-Mar-2015&s=INCY
Idera Pharmaceuticals Inc.'s stock finished Monday's session 5.02% lower at $3.97. A total of 2.34 million shares were traded, which was above its three months average volume of 2.16 million shares. The stock vacillated between $3.88 and $4.15 during the session. Over the previous three trading session and over the last one month, Idera Pharmaceuticals Inc.'s shares have declined 10.38% and 17.81%, respectively. However, over the past three months, the stock has advanced 2.58%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $4.58 is greater than its 200-day moving average of $3.31. Idera Pharmaceuticals Inc.'s stock has an RSI of 41.32. Free in depth research on IDRA is available at:
http://get.Investor-Edge.com/pdf/?c=Idera%20Pharma&d=24-Mar-2015&s=IDRA
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article